UK NHS Pharmaceutical Approval Body Rejects GSK’s Lupus Drug Benlysta

• By: Staff Editor
• Date: May 14, 2012

GSK’s new medicine for treating Lupus – Benlysta (generically known as ‘Belimubab’) was rejected by the UK National Health Service’s (NHS) drug rationing body. The drug was discovered by Human Genome Sciences and developed by Glaxo SmithKline (GSK) to combat the disease that causes the immune system to attack joints and organs. This article details why the drug was rejected and outlines the NHS drug approval process.